ETR:MOR MorphoSys (MOR) Stock Price, News & Analysis €67.25 0.00 (0.00%) (As of 08/20/2024) Add Compare Share Share Today's Range€66.70▼€67.3050-Day Range€66.80▼€68.0552-Week Range€14.52▼€69.75Volume5,144 shsAverage Volume153,687 shsMarket Capitalization$2.53 billionP/E RatioN/ADividend Yield1.26%Price TargetN/A Stock AnalysisStock AnalysisChartHeadlinesStock AnalysisChartHeadlines Get MorphoSys alerts: Email Address Ad Porter & CompanyWhy billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. Click here for my exclusive video About MorphoSys Stock (ETR:MOR)MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Read More MOR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MOR Stock News HeadlinesAugust 28, 2024 | finance.yahoo.comERAS Sep 2024 2.500 put (ERAS240920P00002500)August 17, 2024 | finance.yahoo.comMORF Sep 2024 40.000 put (MORF240920P00040000)September 7, 2024 | Paradigm Press (Ad) Fmr CIA Advisor reveals PEACEMAKER superweaponKamala cannot get the “codes” to this superweapon. In Trump’s hands, it will restore America’s global dominance. It could also help Americans struggling under Bidenomics by potentially sending 5 military stocks SOARING. Historically, similar stocks have shot up 16,270% in just 18 months.May 17, 2024 | benzinga.comLatest News for MorphoSys Stock (NASDAQ:MOR)May 16, 2024 | msn.comMorphoSys gains after Novartis discloses all tender offer conditions were metMay 2, 2024 | finance.yahoo.comUPDATE 2-Novartis to buy radiology drug specialist Mariana for $1 billionApril 30, 2024 | seekingalpha.comMorphoSys: Hold Rating Until The Novartis Deal ClosesApril 29, 2024 | msn.comGermany stocks mixed at close of trade; DAX down 0.16%September 7, 2024 | Paradigm Press (Ad) Fmr CIA Advisor reveals PEACEMAKER superweaponKamala cannot get the “codes” to this superweapon. In Trump’s hands, it will restore America’s global dominance. It could also help Americans struggling under Bidenomics by potentially sending 5 military stocks SOARING. Historically, similar stocks have shot up 16,270% in just 18 months.April 28, 2024 | msn.comNew safety risk for MorphoSys drug could complicate Novartis deal - STATApril 28, 2024 | markets.businessinsider.comMorphoSys earnings: here's what Wall Street expectsApril 24, 2024 | finance.yahoo.comMorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual MeetingApril 11, 2024 | msn.comGerman biopharma MorphoSys recommends Novartis offer be acceptedApril 11, 2024 | finanznachrichten.deNovartis Pharma AG: Novartis tender offer for MorphoSys AG commencesApril 11, 2024 | finance.yahoo.comNovartis tender offer for MorphoSys AG commencesApril 11, 2024 | msn.comNovartis begins tender offer for cancer-focused MorphoSysApril 11, 2024 | msn.comNovartis commences tender offer for MorphoSysApril 11, 2024 | finance.yahoo.comUPDATE 2-Novartis begins tender offer for cancer-focused MorphoSysSee More Headlines Receive MOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MorphoSys and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeETR SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolETR:MOR CUSIPN/A CIKN/A Webwww.morphosys.de Phone+49-89-899270FaxN/AEmployees730Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)(€5.53) Trailing P/E RatioN/A Forward P/E Ratio322.58 P/E Growth0.06Net Income$-468,570,000.00 Net Margins-190.61% Pretax MarginN/A Return on Equity-183.80% Return on Assets-13.84% Debt Debt-to-Equity Ratio3,454.18 Current Ratio1.38 Quick Ratio3.49 Sales & Book Value Annual Sales$241.47 million Price / Sales10.49 Cash Flow€129.73 per share Price / Cash Flow0.52 Book Value(€6.96) per share Price / Book-9.66Miscellaneous Outstanding Shares37,660,000Free FloatN/AMarket Cap$2.53 billion OptionableNot Optionable Beta0.66 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Jean-Paul Kress M.D. (Age 59)Chairman of Management Board, MD & CEO Comp: $1.76MDr. Lucinda Crabtree Ph.D. (Age 45)CFO & Member of Management Board Comp: $705.82kMs. Charlotte Lohmann (Age 54)Chief Legal and Human Resources Officer & Member of Management Board Comp: $474.1kMr. Klaus De WallHead of Accounting & TaxDr. Margit UrbanHead of Discovery Alliances & TechnologiesDr. Julia Neugebauer Ph.D.Head of Investor RelationsDr. Barbara Krebs-Pohl Ph.D.Chief Business OfficerDr. Günter WellnhoferHead of Technical OperationsDr. Harald WatzkaHead of Alliance ManagementMs. Yen Ching ChuaHead of Clinical OperationsMore ExecutivesKey Competitorsad pepper media InternationalETR:APMGenfitEPA:GNFTTeva Pharmaceutical IndustriesFRA:TEVMerck KGaAETR:MRKBiotest AktiengesellschaftETR:BIOView All Competitors MOR Stock Analysis - Frequently Asked Questions How have MOR shares performed this year? MorphoSys' stock was trading at €34.00 at the beginning of 2024. Since then, MOR stock has increased by 97.8% and is now trading at €67.25. View the best growth stocks for 2024 here. What other stocks do shareholders of MorphoSys own? Based on aggregate information from My MarketBeat watchlists, some other companies that MorphoSys investors own include Novo Nordisk A/S (NVO), Gilead Sciences (GILD), SolarEdge Technologies (SEDG), Supernus Pharmaceuticals (SUPN), AbbVie (ABBV), Abbott Laboratories (ABT) and MercadoLibre (MELI). This page (ETR:MOR) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MorphoSys AG Please log in to your account or sign up in order to add this asset to your watchlist. Share MorphoSys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.